Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States

Author:

Reifsnider Odette S.1ORCID,Tafazzoli Ali1ORCID,Linden Stephan2ORCID,Ishak Jack1ORCID,Rakonczai Pal3,Stargardter Matthew1,Kuti Effie4

Affiliation:

1. Evidera Bethesda MD

2. Boehringer Ingelheim International GmbH Ingelheim am Rhein Germany

3. Evidera Budapest Hungary

4. Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield CT

Abstract

Background In the EMPEROR‐Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), empagliflozin plus standard of care reduced the composite of cardiovascular death or hospitalization for heart failure versus standard of care in adults with heart failure with reduced ejection fraction. This analysis investigated the cost‐effectiveness of the 2 regimens from the perspective of US payors. Methods and Results A Markov cohort model was developed based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score quartiles and death. Transition probabilities between health states, risk of cardiovascular/all‐cause death, hospitalization for heart failure and adverse events, treatment discontinuation, and health utilities were estimated from trial data. Medicare and commercial payment rates were combined for treatment acquisition, acute event management, and disease management. An annual discount rate of 3% was used. Empagliflozin plus standard of care yielded 18% fewer hospitalizations for heart failure and 6% fewer deaths versus standard of care over a lifetime, providing cost‐offsets while adding 0.19 life years and 0.19 quality‐adjusted life years at an incremental cost of $16 815/patient. The incremental cost‐effectiveness ratio was $87 725/quality‐adjusted life years gained. Results were consistent across payors, subpopulations, and in deterministic sensitivity analyses. In probabilistic sensitivity analyses, empagliflozin plus standard of care was cost‐effective in 3%, 62%, and 80% of iterations at thresholds of $50 000, $100 000, and $150 000/quality‐adjusted life years. Conclusions Empagliflozin plus standard of care may prevent hospitalizations for heart failure, extend life, and increase quality‐adjusted life years for patients with heart failure with reduced ejection fraction at an acceptable cost for US payors.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3